202 related articles for article (PubMed ID: 26372815)
21. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
Palma G; Conte C; Barbieri A; Bimonte S; Luciano A; Rea D; Ungaro F; Tirino P; Quaglia F; Arra C
Int J Pharm; 2014 Oct; 473(1-2):55-63. PubMed ID: 24992317
[TBL] [Abstract][Full Text] [Related]
22. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
[TBL] [Abstract][Full Text] [Related]
23. Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.
Godugu C; Doddapaneni R; Safe SH; Singh M
Eur J Pharm Biopharm; 2016 Nov; 108():168-179. PubMed ID: 27586082
[TBL] [Abstract][Full Text] [Related]
24. Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies.
Saremi S; Dinarvand R; Kebriaeezadeh A; Ostad SN; Atyabi F
Biomed Res Int; 2013; 2013():150478. PubMed ID: 23971023
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance.
Shi C; Zhang Z; Shi J; Wang F; Luan Y
Int J Pharm; 2015 Nov; 495(2):932-9. PubMed ID: 26456262
[TBL] [Abstract][Full Text] [Related]
27. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
[TBL] [Abstract][Full Text] [Related]
28. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.
Doddapaneni R; Patel K; Chowdhury N; Singh M
Sci Rep; 2017 Nov; 7(1):15824. PubMed ID: 29158480
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism.
Gut I; Danielová V; Holubová J; Soucek P; Klucková H
Arch Toxicol; 2000 Oct; 74(8):437-46. PubMed ID: 11097380
[TBL] [Abstract][Full Text] [Related]
30. pH-sensitive docetaxel-loaded D-α-tocopheryl polyethylene glycol succinate-poly(β-amino ester) copolymer nanoparticles for overcoming multidrug resistance.
Zhao S; Tan S; Guo Y; Huang J; Chu M; Liu H; Zhang Z
Biomacromolecules; 2013 Aug; 14(8):2636-46. PubMed ID: 23815156
[TBL] [Abstract][Full Text] [Related]
31. Sulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel.
Wu J; Shen Q; Fang L
Drug Dev Ind Pharm; 2013 Jul; 39(7):1010-9. PubMed ID: 22681515
[TBL] [Abstract][Full Text] [Related]
32. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
[TBL] [Abstract][Full Text] [Related]
33. Preparation of Deoxycholate-Modified Docetaxel-Cimetidine Complex Chitosan Nanoparticles to Improve Oral Bioavailability.
Xu Y; Fang T; Yang Y; Sun L; Shen Q
AAPS PharmSciTech; 2019 Sep; 20(7):302. PubMed ID: 31489504
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
36. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
Otová B; Václavíková R; Danielová V; Holubová J; Ehrlichová M; Horský S; Soucek P; Simek P; Gut I
Eur J Pharm Sci; 2006 Dec; 29(5):442-50. PubMed ID: 17000091
[TBL] [Abstract][Full Text] [Related]
37. Taxanes: old drugs, new oral formulations.
Jibodh RA; Lagas JS; Nuijen B; Beijnen JH; Schellens JH
Eur J Pharmacol; 2013 Oct; 717(1-3):40-6. PubMed ID: 23660368
[TBL] [Abstract][Full Text] [Related]
38. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
Kamath AV; Chong S; Chang M; Marathe PH
Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
[TBL] [Abstract][Full Text] [Related]
40. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Cho YA; Lee W; Choi JS
Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
